PRECAUTIONS O
General O
Needles O
or O
intravenous O
administration O
sets O
containing O
aluminum O
parts O
that O
may O
come O
in O
contact O
with O
carboplatin O
injection O
should O
not O
be O
used O
for O
the O
preparation O
or O
administration O
of O
the O
drug O
. O

Aluminum O
can O
react O
with O
carboplatin O
causing O
precipitate O
formation O
and O
loss O
of O
potency O
. O

Drug O
Interactions O
The O
renal O
effects O
of O
nephrotoxic B-NonOSE_AE
compounds O
may O
be O
potentiated O
by O
carboplatin O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
The O
carcinogenic O
potential O
of O
carboplatin O
has O
not O
been O
studied O
, O
but O
compounds O
with O
similar O
mechanisms O
of O
action O
and O
mutagenicity O
profiles O
have O
been O
reported O
to O
be O
carcinogenic B-NonOSE_AE
. O

Carboplatin O
has O
been O
shown O
to O
be O
mutagenic B-OSE_Labeled_AE
both O
in O
vitro O
and O
in O
vivo O
. O

It O
has O
also O
been O
shown O
to O
be O
embryotoxic B-NonOSE_AE
and O
teratogenic B-NonOSE_AE
in O
rats O
receiving O
the O
drug O
during O
organogenesis O
. O

Secondary B-NonOSE_AE
malignancies I-NonOSE_AE
have O
been O
reported O
in O
association O
with O
multi-drug O
therapy O
. O

Pregnancy O
Pregnancy O
Category O
D O
See O
WARNINGS O
. O

Nursing O
Mothers O
It O
is O
not O
known O
whether O
carboplatin O
is O
excreted O
in O
human O
milk O
. O

Because O
there O
is O
a O
possibility O
of O
toxicity O
in O
nursing O
infants O
secondary O
to O
carboplatin O
treatment O
of O
the O
mother O
, O
it O
is O
recommended O
that O
breastfeeding O
be O
discontinued O
if O
the O
mother O
is O
treated O
with O
carboplatin O
injection O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
in O
pediatric O
patients O
have O
not O
been O
established O
( O
see O
WARNINGS O
, O
" B-NonOSE_AE
audiologic I-NonOSE_AE
toxicity I-NonOSE_AE
" I-NonOSE_AE
) O
. O

Geriatric O
Use O
Of O
the O
789 O
patients O
in O
initial O
treatment O
combination O
therapy O
studies O
( O
NCIC O
and O
SWOG O
) O
, O
395 O
patients O
were O
treated O
with O
carboplatin O
in O
combination O
with O
cyclophosphamide O
. O

Of O
these O
, O
141 O
were O
over O
65 O
years O
of O
age O
and O
22 O
were O
75 O
years O
or O
older O
. O

In O
these O
trials O
, O
age O
was O
not O
a O
prognostic O
factor O
for O
survival O
. O

In O
terms O
of O
safety O
, O
elderly O
patients O
treated O
with O
carboplatin O
were O
more O
likely O
to O
develop O
severe O
thrombocytopenia B-OSE_Labeled_AE
than O
younger O
patients O
. O

In O
a O
combined O
database O
of O
1,942 O
patients O
( O
414 O
were O
> O
= O
65 O
years O
of O
age O
) O
that O
received O
single O
agent O
carboplatin O
for O
different O
tumor B-Not_AE_Candidate
types O
, O
a O
similar O
incidence O
of O
adverse O
events O
was O
seen O
in O
patients O
65 O
years O
and O
older O
and O
in O
patients O
less O
than O
65 O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
elderly O
and O
younger O
patients O
, O
but O
greater O
sensitivity O
of O
some O
older O
individuals O
can O
not O
be O
ruled O
out O
. O

Because O
renal B-NonOSE_AE
function I-NonOSE_AE
is I-NonOSE_AE
often I-NonOSE_AE
decreased I-NonOSE_AE
in O
the O
elderly O
, O
renal O
function O
should O
be O
considered O
in O
the O
selection O
of O
carboplatin O
injection O
dosage O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

